A super expensive component of the US healthcare system: cardiometabolic diseases (such as diabetes and hypertension). While new "wonder drugs" like Ozempic have come to market to huge demand, there's still a need to combine behavioral change with these treatments to create sustainable change (especially as costs rise). Vida Health is one of the companies positioned in this area, creating a holistic digital-first treatment option for cardiometabolic disease. This space will undoubtably get more crowded as additional data from Ozempic continues to show its various interactions beyond just weight loss, but Vida's been around for around a decade and has established many different programs, including Spanish speaking programs. (May 2024)